192 related articles for article (PubMed ID: 24464500)
1. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
2. Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors.
Chen J; Nagle AM; Wang YF; Boone DN; Lee AV
J Biol Chem; 2018 Mar; 293(10):3700-3709. PubMed ID: 29330302
[TBL] [Abstract][Full Text] [Related]
3. Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells.
ter Braak B; Wink S; Koedoot E; Pont C; Siezen C; van der Laan JW; van de Water B
Breast Cancer Res; 2015 Jul; 17(1):97. PubMed ID: 26187749
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
Sarfstein R; Nagaraj K; LeRoith D; Werner H
Cells; 2019 Nov; 8(12):. PubMed ID: 31771180
[TBL] [Abstract][Full Text] [Related]
5. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
6. Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.
Gong Y; Ma Y; Sinyuk M; Loganathan S; Thompson RC; Sarkaria JN; Chen W; Lathia JD; Mobley BC; Clark SW; Wang J
Neuro Oncol; 2016 Jan; 18(1):48-57. PubMed ID: 26136493
[TBL] [Abstract][Full Text] [Related]
7. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
Chan JY; Hackel BJ; Yee D
Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
[TBL] [Abstract][Full Text] [Related]
8. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
Chan JY; LaPara K; Yee D
Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
[TBL] [Abstract][Full Text] [Related]
9. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
10. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
11. Proliferative and signaling activities of insulin analogues in endometrial cancer cells.
Aizen D; Sarfstein R; Bruchim I; Weinstein D; Laron Z; Werner H
Mol Cell Endocrinol; 2015 May; 406():27-39. PubMed ID: 25697343
[TBL] [Abstract][Full Text] [Related]
12. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
15. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
16. Systems Analysis of Insulin and IGF1 Receptors Networks in Breast Cancer Cells Identifies Commonalities and Divergences in Expression Patterns.
Sarfstein R; Yeheskel A; Sinai-Livne T; Pasmanik-Chor M; Werner H
Front Endocrinol (Lausanne); 2020; 11():435. PubMed ID: 32733384
[TBL] [Abstract][Full Text] [Related]
17. Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model.
ter Braak B; Siezen C; Speksnijder EN; Koedoot E; van Steeg H; Salvatori DC; van de Water B; van der Laan JW
Breast Cancer Res; 2015 Feb; 17(1):14. PubMed ID: 25848982
[TBL] [Abstract][Full Text] [Related]
18. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells.
Gaben AM; Sabbah M; Redeuilh G; Bedin M; Mester J
BMC Cancer; 2012 Jul; 12():291. PubMed ID: 22799881
[TBL] [Abstract][Full Text] [Related]
19. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
20. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Sciacca L; Cassarino MF; Genua M; Pandini G; Le Moli R; Squatrito S; Vigneri R
Diabetologia; 2010 Aug; 53(8):1743-53. PubMed ID: 20424816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
